Company: BDRX
Filing Date: 2025-05-01
Form Type: DRS
Source: 0001214659-25-006756
Chunk: 158

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-01
Form: DRS
Chunk 158
---
)
an aggregate of 90,999 pre-funded warrants to purchase Depositary Shares to certain of the secured noteholders, and (ii) issued to Melior
Pharmaceuticals I, Inc. 14,177 of our Depositary Shares.

On February 26, 2024, in connection with
our Company’s obligations under a license agreement with Melior, we issued 14,177 Depositary Shares to Bukwang Pharmaceutical Co.
Ltd.

On April 29, 2024, in connection with the
closing of the Emtora License Agreement, we issued 15,136 Depositary Shares to Emtora.

On May 24, 2024, in connection with certain
warrant inducement agreements, we issued an aggregate of 124,181 Depositary Shares to certain holders of our Series E Warrants and Series
F Warrants, upon the exercise of 62,906 Series E Warrants and 61,275 Series F Warrants, at an exercise price of $37.50 per share. In addition,
we issued to such holders an aggregate of 94,358 Series G Warrants, and 147,805 Series H Warrants. The aggregate gross proceeds to the
Company were approximately $6.05 million, before deducting agent fees and expenses. Additionally, we issued warrants to purchase 6,456
of our Depositary Shares in connection with the offering to Ladenburg, as agent, and certain designees of Ladenburg.

On July 22, 2024, in a private placement, we issued and sold (x) Series J Warrants exercisable for 213,188 Depositary Shares, and (y) Series K Warrants to purchase an aggregate of 213,188 Depositary Shares. The warrants are immediately exercisable at an exercise price of $25.00 per Depositary Share, subject to adjustments for certain dilutive equity issuances. The aggregate gross proceeds to the Company were approximately $5.0 million (including shares sold in a concurrent registered direct offering). Additionally, we issued warrants to purchase 8,525 of our Depositary Shares in connection with the offering to Ladenburg, as the placement agent in the offering, and certain of its designees.

| Item  8. | Exhibits and Financial Statement Schedules |

| (a) | The Exhibit Index is incorporated herein by reference. |

See the Exhibit Index attached to this registration
statement, which is incorporated herein by reference.

| (b) | Financial